X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Sells $34,412.85 in Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Paula Ragan sold 76,473 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the sale, the chief executive officer now owns 1,087,386 shares in the company, valued at approximately $489,323.70. This represents a 6.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

X4 Pharmaceuticals Stock Performance

XFOR opened at $0.74 on Thursday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. The stock has a market capitalization of $125.39 million, a price-to-earnings ratio of -8.17 and a beta of 0.14. The company has a fifty day moving average of $0.55 and a 200 day moving average of $0.61. X4 Pharmaceuticals, Inc. has a fifty-two week low of $0.26 and a fifty-two week high of $1.60.

Wall Street Analysts Forecast Growth

A number of research firms have commented on XFOR. HC Wainwright reaffirmed a “buy” rating and issued a $1.50 target price on shares of X4 Pharmaceuticals in a research report on Tuesday, January 14th. Stifel Nicolaus reduced their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, November 14th.

Institutional Trading of X4 Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP bought a new stake in shares of X4 Pharmaceuticals in the 3rd quarter valued at about $340,000. AQR Capital Management LLC raised its stake in X4 Pharmaceuticals by 1,080.3% in the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after buying an additional 388,115 shares in the last quarter. State Street Corp lifted its holdings in X4 Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after buying an additional 189,105 shares during the period. Barclays PLC boosted its position in X4 Pharmaceuticals by 196.0% during the 3rd quarter. Barclays PLC now owns 277,682 shares of the company’s stock valued at $185,000 after acquiring an additional 183,861 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of X4 Pharmaceuticals by 233.0% in the 4th quarter. SG Americas Securities LLC now owns 183,152 shares of the company’s stock valued at $134,000 after acquiring an additional 128,148 shares during the period. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.